The generic name for Ubrelvy is ubrogepant [1]. Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine with or without aura in adults [1][2].
How does Ubrelvy (ubrogepant) work?
Ubrogepant works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [2]. By inhibiting CGRP, ubrogepant can help to reduce migraine-related inflammation and pain [2].
When can I expect a generic version of Ubrelvy to be available?
The availability of generic versions of Ubrelvy depends on patent expirations and any potential legal challenges to those patents. Information on specific patent dates and potential generic entry can be found through resources like DrugPatentWatch.com [3].
What are the differences between Ubrelvy and other migraine treatments?
Ubrelvy (ubrogepant) is a newer class of acute migraine treatment known as CGRP receptor antagonists. Unlike older treatments such as triptans, which target serotonin receptors, ubrogepant directly targets the CGRP pathway [2]. This difference in mechanism can be significant for patients who do not respond well to or cannot tolerate triptans [2].
What are the common side effects of Ubrelvy?
Common side effects reported for ubrogepant include nausea, fatigue, and dry mouth [1].
Where can I find information on Ubrelvy patents and exclusivity?
Information regarding Ubrelvy's patent status, including expiration dates and potential for generic competition, is tracked by organizations that monitor drug patents. DrugPatentWatch.com provides such data [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/ubrelvy
[2] https://www.drugpatentwatch.com/search?q=ubrogepant
[3] https://www.drugpatentwatch.com